University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
NCT Number: NCT01780038
Innovative strategies to reduce adult smoking prevalence include using genetic information to motivate cessation and, ultimately, to tailor cessation pharmacotherapy. Success of these interventions depends, in part, on smokers' interest and participation in genetic testing related to cessation and their understanding and use of the results (i.e., their genetic literacy). The recent availability of genetic risk testing for a nicotinic acetylcholine receptor gene (CHRNA3) variant (rs105173) associated with nicotine dependence makes it highly feasible to investigate smokers' interest in and use of genetic information about nicotine dependence. Therefore, the primary purpose of this study is to determine the impact of an intervention that provides smokers with an educational session about genetic contributions to smoking and nicotine dependence plus their genotype results for rs1051730 on smoking cessation outcomes compared to those who receive only the educational session. Secondary purposes are to determine: (a) the impact of genetic education and knowing personal genotype results on genetic literacy outcomes and (b) the feasibility of recruitment and retention methods in a study addressing genotyping for nicotine dependence. Primary outcomes are cessation-related behaviors and cognitions indicating abstinence. Secondary outcomes are cognitions and emotions indicating genetic literacy. Knowledge gained from this study has the potential for clinical translation so that as genotyping becomes part of smoking cessation, health-care providers can understand and address factors influencing smokers' adaptation to genetically-informed cessation treatment. The study will use a longitudinal, repeated measures design (experimental, control; N=90; 45/group). All participants will receive a 90-minute educational session about genetic contributions for smoking and nicotine dependence and will donate a buccal swab sample for genotyping. The investigators will then randomize participants to two groups: those who receive genotyping results in a genetic counseling session (experimental) and those who do not (control). Follow-up data will be collected from both groups at baseline and weeks 2, 6, 10 after the experimental group receives genotyping results, with a brief follow-up and study termination occurring at week 12. Control group participants will be offered their genotyping results at the end of the study.
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Not applicable
Omaha, Nebraska, 68198, United States
The primary aim of this study is:
Aim 1. Determine the impact of knowing personal genotyping results for nicotine dependence risk on the smoking cessation (primary) outcomes at weeks 2, 6, and 10.
The working hypotheses for the cessation-related behaviors are:
The working hypotheses for the cessation-related cognitions are:
The secondary aims are:
Aim 2. Determine the impact of knowing personal genotyping results for nicotine dependence risk on the secondary genetic literacy (secondary) outcomes at weeks 2, 6, and 10.
The working hypotheses for the genetic literacy-related cognitions and emotions are:
Aim 3. Explore smokers' perceptions and experiences that contextualize participation in genetic education and genotyping for nicotine dependence risk. We will conduct focus groups with both the intervention and control group participants at weeks 2 and 6 after intervention group participants receive their genotyping results.
Aim 4. Determine the feasibility of an intervention that informs people of their personal genotype results for nicotine dependence risk for a larger clinical trial, including evaluation of enrollment (recruitment efficiency, attrition, problems and solutions), intervention fidelity (delivery, receipt, enactment), data collection, subject acceptability of the intervention, and estimation of effect sizes for sample size determination in future, larger clinical trials.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The investigators are excluding participants who do not understand, speak or write in English at this time because: (1) the consent document, the educational genetics presentation, and data collection forms are currently written in English only and (2)the resources to make the educational presentation and data collection documents culturally-specific for other cultures are not available. In making the study relevant for non-English speaking participants, it is not only a literal translation the presentation and documents into another language that is needed, but the ideas of health and heredity from the culture related to the language also need to be taken into account when presenting the study and the study materials in another language.
Exclusion criteria
Participants will receive the results of genotyping for RS1051730
Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
Time frame: Assessed at Weeks 6 and 10 after Genotyping Results, Week 10 reported
Abstinence: Point-Prevalence & Continuous Self-Report; Exhaled Carbon Monoxide (CO): <= 6 ppm past 24 hrs.; Salivary Cotinine: <15 ng/ml past 7 days
Time frame: Assessed at Weeks 6 and 10 weeks after Genotyping Results, Week 10 reported.
Use of Pharmacotherapy: Self-report of type and frequency of use of FDA-approved smoking cessation medications.
University of Nebraska
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07366294
Behavior, Behavioral Symptoms
Malang, East Java, Indonesia
View Trial DetailsNCT05095779
Behavior, Chemically-Induced Disorders
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT04429568
Behavior, Blood Coagulation Disorders
San Francisco, California, United States
View Trial DetailsNCT04159571
Addiction, Addiction Nicotine
Winston-Salem, North Carolina, United States
View Trial Details